about
Drug Design for CNS Diseases: Polypharmacological Profiling of Compounds Using Cheminformatic, 3D-QSAR and Virtual Screening MethodologiesHistone Deacetylase Inhibition Activity and Molecular Docking of (E )-Resveratrol: Its Therapeutic Potential in Spinal Muscular AtrophyNew hMAO-A Inhibitors with Potential Antidepressant Activity: Design, Synthesis, Biological Screening and Evaluation of Pharmacological Activity.Design, Synthesis and hMAO Inhibitory Screening of Novel 2-Pyrazoline Analogues.Synthesis and Screening of Human Monoamine Oxidase-A Inhibitor Effect of New 2-Pyrazoline and Hydrazone Derivatives.Synthesis and molecular modeling of some novel hexahydroindazole derivatives as potent monoamine oxidase inhibitors.Insights into the binding mode of new N-substituted pyrazoline derivatives to MAO-A: docking and quantum chemical calculations.Docking studies on monoamine oxidase-B inhibitors: estimation of inhibition constants (K(i)) of a series of experimentally tested compounds.Flavonoids from Sideritis Species: Human Monoamine Oxidase (hMAO) Inhibitory Activities, Molecular Docking Studies and Crystal Structure of Xanthomicrol.Human dopamine transporter: the first implementation of a combined in silico/in vitro approach revealing the substrate and inhibitor specificities.Identification of potential isoform-selective histone deacetylase inhibitors for cancer therapy: a combined approach of structure-based virtual screening, ADMET prediction and molecular dynamics simulation assay.Corrected Panel-Reactive Antibody Positivity Rates for Hypersensitized Patients in Turkish Population With Calculated Panel-Reactive Antibody Software.cis-Cyclopropylamines as mechanism-based inhibitors of monoamine oxidases.In silico identification of novel and selective monoamine oxidase B inhibitors.Synthesis of some novel hydrazone and 2-pyrazoline derivatives: monoamine oxidase inhibitory activities and docking studies.Synthesis, anticancer activity, and molecular modeling of etodolac-thioether derivatives as potent methionine aminopeptidase (type II) inhibitorsEvaluation of selective human MAO inhibitory activities of some novel pyrazoline derivativesSynthesis, molecular modeling, and in vitro screening of monoamine oxidase inhibitory activities of some novel hydrazone derivativesDocking of novel reversible monoamine oxidase-B inhibitors: efficient prediction of ligand binding sites and estimation of inhibitors thermodynamic propertiesEffect of The Locus of The Oxygen Atom in Amino Ethers on the Inactivation of Monoamine Oxidase BObservation of a Flavin Semiquinone in the Resting State of Monoamine Oxidase B by Electron Paramagnetic Resonance and Electron Nuclear Double Resonance Spectroscopy†,‡Synthesis, Molecular Docking and Anticancer Activity of Diflunisal Derivatives as Cyclooxygenase Enzyme InhibitorsCarboxylic acid derivatives display potential selectivity for human histone deacetylase 6: Structure-based virtual screening, molecular docking and dynamics simulation studiesThe design of potent HIV-1 integrase inhibitors by a combined approach of structure-based virtual screening and molecular dynamics simulationCrystallographic structure versus homology model: a case study of molecular dynamics simulation of human and zebrafish histone deacetylase 10Homology modeling of human histone deacetylase 10 and design of potential selective inhibitorsExamining the stability of binding modes of the co-crystallized inhibitors of human HDAC8 by molecular dynamics simulationDrug repurposing for coronavirus (COVID-19): in silico screening of known drugs against coronavirus 3CL hydrolase and protease enzymesSynthesis, molecular modeling, in vivo study, and anticancer activity of 1,2,4-triazole containing hydrazide-hydrazones derived from (S)-naproxenPharmacophore-based virtual screening for identification of potential selective inhibitors of human histone deacetylase 6
P50
Q26745421-F595CD16-B03C-466C-AF92-2F38BE1E1A93Q29011953-BD74C3E6-8BF6-412D-B5FD-BB4E529520B5Q38802726-2E5434A8-A220-45C0-971E-B3E1F5F46A37Q38802729-A060D5D0-38DC-4A1D-80D7-00F255863B1AQ40621702-330FA724-103C-44C6-9790-28FE3E390FF0Q43291522-1D902033-214A-4BB0-BA48-33E5E7F0142AQ44508670-413D0685-66A4-474C-8354-E04A94687727Q46683046-09A42DAE-BBFE-49EA-896F-5A9360F8348EQ46737135-5DD0C188-E422-426B-8DFD-E31F6804B32CQ47555822-B7A9F020-84F5-4665-BBCC-1049D3594DE5Q47645910-A42B5DEA-CD89-4122-837F-DC8EFA754A2CQ47810059-DDF1AE3D-D9AC-46B4-B14B-087923DE569CQ48099692-40F5999C-6F5A-48DB-82FF-2BC9C9FE30F3Q48252391-A3C5E2CF-D661-471F-A4F2-443074F9A46EQ53511599-1C1D5217-E6ED-4BAD-B060-12D1E48A15EBQ57013033-7758AD88-6DF8-43BC-8D18-74C4BE003BB6Q57013050-8212B2A8-7C07-41DA-A026-879965AFAEB2Q57013055-334D4A60-EE10-441C-99A3-3AED618CCD89Q57013065-8B86702B-C0DA-485C-895A-338439E6813CQ57013079-FF0D1073-44C9-4966-9285-7D7EA834E2D4Q57013085-5325F364-3CFD-4176-A439-A61B5A68D7DFQ58697094-6BB989A6-AB05-4FE6-9AD0-50F30C8EA9D7Q88957951-C6394AC3-C5DD-4AFF-BAFF-D7F8F2188B54Q90336129-0404CCB9-ACA8-4F50-8312-FAED7C914653Q91182983-02D3FBEE-8C98-49FE-97E7-B6A31D6566A2Q91380670-5FDA0880-69CC-4473-8906-5C5DA091B9E0Q91774549-B358731F-685F-4093-AD5F-646792C3DF98Q92048014-10E24B18-573E-49CC-9ECB-B4F47893AF90Q92210816-374CD29B-0A26-4491-B64C-7A81D9A4DCDCQ93274215-8CC7CE38-FC63-420E-9809-416B7FBBEB46
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Kemal Yelekci
@ast
Kemal Yelekci
@en
Kemal Yelekci
@es
Kemal Yelekci
@nl
Kemal Yelekci
@sl
type
label
Kemal Yelekci
@ast
Kemal Yelekci
@en
Kemal Yelekci
@es
Kemal Yelekci
@nl
Kemal Yelekci
@sl
prefLabel
Kemal Yelekci
@ast
Kemal Yelekci
@en
Kemal Yelekci
@es
Kemal Yelekci
@nl
Kemal Yelekci
@sl
P106
P21
P31
P496
0000-0002-0052-4926